105 related articles for article (PubMed ID: 16979647)
1. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells.
Turner NA; Hall KT; Ball SG; Porter KE
Atherosclerosis; 2007 Jul; 193(1):36-43. PubMed ID: 16979647
[TBL] [Abstract][Full Text] [Related]
2. Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells.
Turner NA; Ho S; Warburton P; O'Regan DJ; Porter KE
J Vasc Surg; 2007 May; 45(5):1022-8. PubMed ID: 17466797
[TBL] [Abstract][Full Text] [Related]
3. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9.
Porter KE; Turner NA
Biochem Soc Trans; 2002 Apr; 30(2):120-6. PubMed ID: 12023838
[TBL] [Abstract][Full Text] [Related]
4. The -1562C/T MMP-9 promoter polymorphism does not predict MMP-9 expression levels or invasive capacity in saphenous vein smooth muscle cells cultured from different patients.
Maqbool A; Turner NA; Galloway S; Riches K; O'Regan DJ; Porter KE
Atherosclerosis; 2009 Dec; 207(2):458-65. PubMed ID: 19541314
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration.
Porter KE; Naik J; Turner NA; Dickinson T; Thompson MM; London NJ
J Vasc Surg; 2002 Jul; 36(1):150-7. PubMed ID: 12096273
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels.
Turner NA; O'Regan DJ; Ball SG; Porter KE
FASEB J; 2005 May; 19(7):804-6. PubMed ID: 15728660
[TBL] [Abstract][Full Text] [Related]
7. MMP-3 (5A/6A) polymorphism does not influence human smooth muscle cell invasion.
Maqbool A; Keswani A; Galloway S; O'Regan DJ; Ball SG; Turner NA; Porter KE
J Surg Res; 2012 Jun; 175(2):343-9. PubMed ID: 21601886
[TBL] [Abstract][Full Text] [Related]
8. Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits.
Yongxin S; Wenjun D; Qiang W; Yunqing S; Liming Z; Chunsheng W
Ann Thorac Surg; 2013 Jan; 95(1):55-61. PubMed ID: 23146278
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cell cycle entry by PTEN in smooth muscle cell proliferation of human coronary artery bypass conduits.
Jia G; Mitra AK; Gangahar DM; Agrawal DK
J Cell Mol Med; 2009 Mar; 13(3):547-54. PubMed ID: 18544045
[TBL] [Abstract][Full Text] [Related]
10. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.
Mitra AK; Jia G; Gangahar DM; Agrawal DK
J Cell Mol Med; 2009 Jan; 13(1):177-87. PubMed ID: 18363844
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization.
Johnson C; Galis ZS
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):54-60. PubMed ID: 14551157
[TBL] [Abstract][Full Text] [Related]
12. Potentially positive ageing-related variations of medial smooth muscle cells in the saphenous veins used as aortocoronary bypass grafts.
Perek B; Malinska A; Gasowski J; Ostalska-Nowicka D; Perek A; Jemielity M; Zabel M; Nowicki M
Folia Histochem Cytobiol; 2016; 54(2):91-98. PubMed ID: 27845500
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.
Bellosta S; Baetta R; Canavesi M; Comparato C; Granata A; Monetti M; Cairoli F; Eberini I; Puglisi L; Corsini A
Pharmacol Res; 2007 Aug; 56(2):160-7. PubMed ID: 17582780
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes.
Sun Y; Kang L; Li J; Liu H; Wang Y; Wang C; Zou Y
J Cell Mol Med; 2016 Oct; 20(10):1945-55. PubMed ID: 27297874
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity.
Riches K; Warburton P; O'Regan DJ; Turner NA; Porter KE
Cardiovasc Revasc Med; 2014 Apr; 15(3):141-8. PubMed ID: 24642103
[TBL] [Abstract][Full Text] [Related]
16. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.
Augé N; Maupas-Schwalm F; Elbaz M; Thiers JC; Waysbort A; Itohara S; Krell HW; Salvayre R; Nègre-Salvayre A
Circulation; 2004 Aug; 110(5):571-8. PubMed ID: 15277330
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
18. Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting.
Perek B; Malinska A; Misterski M; Ostalska-Nowicka D; Zabel M; Perek A; Nowicki M
Biomed Res Int; 2013; 2013():730721. PubMed ID: 24151618
[TBL] [Abstract][Full Text] [Related]
19. AP-1 inhibits expression of MMP-2/9 and its effects on rat smooth muscle cells.
Zhang HW; Wang X; Zong ZH; Huo X; Zhang Q
J Surg Res; 2009 Nov; 157(1):e31-7. PubMed ID: 19524937
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia.
Kuzuya M; Kanda S; Sasaki T; Tamaya-Mori N; Cheng XW; Itoh T; Itohara S; Iguchi A
Circulation; 2003 Sep; 108(11):1375-81. PubMed ID: 12939223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
